NFL Biosciences Company Description

NFL Biosciences SA, a biotechnology company, engages in the development of natural addiction withdrawal solutions for smokers.

Its pipeline includes NFL-101, a drug candidate for smoking cessation, currently under Phase 2b clinical trials; NFL-201, a drug candidate for cannabis addiction currently in preclinical stage; and NFL-301, a drug candidate for reducing alcohol consumption, currently under in preclinical stage.

The company was incorporated in 2006 and is based in Castelnau-le-Lez, France.

NFL Biosciences SA

Country	France
Founded	2006
Industry	Biotechnology
Sector	Healthcare
CEO	Ignacio Faus

Contact Details

Address: 199 Rue HElEne Boucher Castelnau-le-Lez, 34170 France
Phone	33 4 11 93 76 67
Website	nflbiosciences.com

Stock Details

Ticker Symbol	ALNFL
Exchange	Euronext Paris
Reporting Currency	EUR
ISIN Number	FR0014003XT0
SIC Code	2836

Key Executives

Name	Position
Dr. Ignacio Faus M.B.A., Ph.D.	Chief Executive Officer and Chairman
Bruno Lafont M.B.A., M.Sc.	Co-Founder, Chief Operating Officer and Director
Guillaume Audema	Chief Financial Officer